Core Viewpoint - Pomerantz LLP is investigating potential securities fraud or unlawful business practices involving NeoGenomics and its officers or directors, following disappointing financial results and a significant stock price drop [1][3][4]. Financial Performance - NeoGenomics reported second-quarter 2025 revenue of $181.3 million, which was below consensus estimates [3]. - The company experienced a net loss of $45.1 million during the same period [3]. - NeoGenomics revised its 2025 revenue forecast down to a range of $720 million to $726 million, a decrease from the previous estimate of approximately $753 million [3]. - The adjusted EBITDA projection was also lowered to a range of $41 million to $44 million, down from a prior range of $55 million to $58 million [3]. Stock Market Reaction - Following the release of the financial results, NeoGenomics' stock price fell by $1.21 per share, or 18.73%, closing at $5.25 per share on July 29, 2025 [4].

Core Viewpoint - Pomerantz LLP is investigating potential securities fraud or unlawful business practices involving NeoGenomics and its officers or directors, following disappointing financial results and a significant stock price drop [1][3][4]. Financial Performance - NeoGenomics reported second-quarter 2025 revenue of $181.3 million, which was below consensus estimates, and a net loss of $45.1 million [3]. - The company revised its 2025 revenue forecast down to a range of $720 million to $726 million, a decrease from the previous estimate of approximately $753 million [3]. - Adjusted EBITDA projections were also lowered to a range of $41 million to $44 million, down from a prior range of $55 million to $58 million [3]. Stock Market Reaction - Following the release of the financial results, NeoGenomics' stock price fell by $1.21 per share, or 18.73%, closing at $5.25 per share on July 29, 2025 [4].

Core Viewpoint - NeoGenomics, Inc. is facing scrutiny due to potential securities fraud or unlawful business practices, as indicated by an investigation initiated by Pomerantz LLP on behalf of investors [1] Financial Performance - For Q2 2025, NeoGenomics reported revenue of $181.3 million, which was below consensus estimates [2] - The company recorded a net loss of $45.1 million for the same quarter [2] - NeoGenomics has revised its 2025 revenue forecast to a range of $720 million to $726 million, down from a previous estimate of approximately $753 million [2] - The adjusted EBITDA projection was also lowered to a range of $41 million to $44 million from a prior range of $55 million to $58 million [2] Market Reaction - Following the announcement of its financial results, NeoGenomics' stock price decreased by $1.21 per share, or 18.73%, closing at $5.25 per share on July 29, 2025 [3]

Group 1 - NeoGenomics (NEO) has experienced a significant decline of 29.2% over the past four weeks, but it is now in oversold territory, indicating a potential trend reversal [1] - The Relative Strength Index (RSI) for NEO is currently at 25.23, suggesting that the heavy selling pressure may be exhausting itself [5] - There is a strong consensus among Wall Street analysts that NEO will report better earnings than previously predicted, with a 1.4% increase in the consensus EPS estimate over the last 30 days [6] Group 2 - NEO holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate revisions and EPS surprises, indicating a potential turnaround [7]

Financial Data and Key Metrics Changes - Total revenue for Q2 2025 was $181 million, representing a 10% year-over-year growth, slightly below guidance [7][20] - Clinical revenue increased by 16% year-over-year, with organic clinical revenue at $160 million, reflecting a 13% growth driven by a 10% increase in test volumes [20][21] - Non-clinical revenue declined by 26% year-over-year, primarily due to weakness in pharma revenue [21] - Adjusted EBITDA was $10.7 million, down 2% from the prior year, marking the eighth consecutive quarter of positive adjusted EBITDA [21][22] - Cash flow from operations improved by 44% year-over-year to $20 million, with cash and marketable securities totaling $164 million at the end of the quarter [25] Business Line Data and Key Metrics Changes - NGS testing accounted for 32% of total clinical revenue, growing by 23% year-over-year, slightly below the 25% target [20][21] - Average revenue per clinical test increased by 2% to $461, with a 3% growth excluding Pathline [22] - The launch of the pan tracer liquid biopsy is expected to positively impact NGS growth later in the year [9][20] Market Data and Key Metrics Changes - The macro environment for pharma has created significant headwinds, including NIH funding uncertainty and drug pricing challenges, leading to budget restrictions and project delays [10][39] - The MRD market represents a significant unmet clinical need, estimated at $30 billion, with potential for transformative cancer care [13][14] Company Strategy and Development Direction - The company is focusing on execution excellence and aligning its cost structure with revenues to rebuild credibility with shareholders [9][16] - Strategic drivers include enhancing customer experience, strengthening community channels, and developing new products [11][12] - The company plans to invest in operating efficiencies, including a LIMS project and digital pathology, to achieve greater operational leverage [10][25] Management's Comments on Operating Environment and Future Outlook - Management acknowledged that Q2 performance was below expectations but remains optimistic about future growth opportunities [6][9] - The company has updated its 2025 financial guidance to reflect current challenges, projecting revenue of $720 million to $726 million, representing 9% to 10% growth [24][25] - Management emphasized the importance of transparency and confidence in guidance, aiming to exceed goals moving forward [32][37] Other Important Information - The company is committed to the MRD space and has ongoing litigation related to RADAR ID, with a trial expected in October [53][55] - The integration of Pathline is on track, with revenues meeting internal expectations and plans to leverage the broader portfolio for cross-selling [80][81] Q&A Session Summary Question: Guidance Setting Process - The CEO discussed the learning curve in setting guidance and the need for transparency and confidence in communicating with investors [32][34] Question: 2025 Guidance Changes - The CEO highlighted that the macro environment for pharma significantly impacted the guidance, accounting for about two-thirds of the changes [39][40] Question: Portfolio Pruning Opportunities - The company is evaluating its portfolio to focus on the most profitable products while maintaining a comprehensive offering for customers [46][51] Question: Non-Clinical Business Viability - Management confirmed commitment to the non-clinical space, citing its strategic value and potential for future growth despite current challenges [72][75] Question: Pathline Integration and Cross-Selling - The integration of Pathline is progressing well, with expectations for enhanced revenue generation through cross-selling in the Northeast [80][81]

Core Viewpoint - NeoGenomics reported quarterly earnings of $0.03 per share, matching the Zacks Consensus Estimate, with revenues of $181.33 million, slightly missing expectations by 0.88% [1][2]. Financial Performance - The company achieved earnings of $0.03 per share, consistent with the previous year, and had a surprise of +100% compared to the expected loss of $0.02 per share a quarter ago [1][2]. - Revenues for the quarter were $181.33 million, up from $164.5 million year-over-year, but the company has only surpassed consensus revenue estimates once in the last four quarters [2]. Stock Performance - NeoGenomics shares have declined approximately 60.8% year-to-date, contrasting with the S&P 500's increase of 8.6% [3]. - The stock's immediate price movement will largely depend on management's commentary during the earnings call [3]. Future Outlook - The current consensus EPS estimate for the upcoming quarter is $0.06 on revenues of $193.17 million, and for the current fiscal year, it is $0.15 on revenues of $744.87 million [7]. - The Zacks Rank for NeoGenomics is 1 (Strong Buy), indicating expectations for the stock to outperform the market in the near future [6]. Industry Context - The Medical - Biomedical and Genetics industry, to which NeoGenomics belongs, is currently ranked in the top 38% of over 250 Zacks industries, suggesting a favorable outlook compared to lower-ranked industries [8].

Financial Performance - Revenue reached $1813 million, a 102% increase compared to the previous year[20],[25] - Adjusted Gross Profit was $824 million, representing a 59% growth[20],[25] - Adjusted EBITDA stood at $107 million, remaining relatively flat compared to the prior year[20],[25] - Cash Flow from Operations increased significantly by 463% to $203 million[20],[25] - NGS revenue experienced substantial growth of 23% year-over-year[23] Margins and Profitability - Adjusted Gross Margin declined by 184 bps to 454%, primarily due to the Pathline acquisition[23],[25] - Adjusted EBITDA excluding Pathline grew by 13% compared to the previous year[23] Guidance and Outlook - The company revised its full-year 2025 revenue guidance to $720-$726 million, indicating a 9-10% year-over-year growth[24] - The company also updated its Adjusted EBITDA guidance for 2025 to $41-$44 million, reflecting a 3-10% year-over-year increase[24] Clinical Performance - Clinical volume reached 357 thousand units in Q2 2025[12] - Clinical revenue was $164 million in Q2 2025[14]

[Report Overview](index=1&type=section&id=Report%20Overview) [Filing Information](index=1&type=section&id=Filing%20Information) This report is NEOGENOMICS, INC.'s quarterly report (Form 10-Q) for the period ended June 30, 2025, incorporated in Nevada, trading under the ticker NEO on Nasdaq, classified as a large accelerated filer, and having submitted all required reports and interactive data files - Company Name: **NEOGENOMICS, INC.** (Registrant)[2](index=2&type=chunk) - Report Type: Quarterly Report (Form 10-Q)[2](index=2&type=chunk) - Reporting Period: Ended June 30, 2025[2](index=2&type=chunk) - Ticker Symbol: **NEO**, listed on the Nasdaq Stock Market[3](index=3&type=chunk) - Company Classification: Large accelerated filer[4](index=4&type=chunk) - As of July 25, 2025, **129,178,622** shares of common stock were outstanding[4](index=4&type=chunk) [Forward-Looking Statements](index=3&type=section&id=Forward-Looking%20Statements) This report contains forward-looking statements regarding the company's strategy, future operations, financial condition, revenue, reimbursement levels, Pathline acquisition synergies, costs, capital expenditures, prospects, and management objectives, which involve known and unknown risks and uncertainties that could cause actual results to differ materially from expectations, with no obligation for the company to update any such statements - Forward-looking statements cover the company's strategy, future operations, financial condition, revenue, reimbursement levels, Pathline acquisition synergies, anticipated costs and capital expenditures, prospects, and management plans and objectives[7](index=7&type=chunk) - These statements involve known and unknown risks and uncertainties that could cause actual results to differ materially from forward-looking statements[7](index=7&type=chunk) - The company undertakes no obligation to update any forward-looking statements to reflect events or circumstances after the report date[7](index=7&type=chunk) [Glossary](index=4&type=section&id=Glossary) This section provides definitions for abbreviations, acronyms, and terms used in this quarterly report to aid reader comprehension of the content - Definitions are provided for key abbreviations and terms used in the report, such as ACA (Affordable Care Act), ACLA (American Clinical Laboratory Association), FDA (U.S. Food and Drug Administration), GAAP (U.S. Generally Accepted Accounting Principles), and NGS (Next-Generation Sequencing)[8](index=8&type=chunk) [PART I FINANCIAL INFORMATION](index=5&type=section&id=PART%20I%20FINANCIAL%20INFORMATION) [Item 1. Financial Statements (unaudited)](index=5&type=section&id=Item%201.%20Financial%20Statements%20(unaudited)) This section presents the company's unaudited condensed consolidated financial statements, including balance sheets, statements of operations, comprehensive loss, stockholders' equity, and cash flows, along with related notes, providing the financial position and operating results as of June 30, 2025 [Condensed Consolidated Balance Sheets](index=5&type=section&id=Condensed%20Consolidated%20Balance%20Sheets) As of June 30, 2025, total assets were **$1,393,950 thousand**, a decrease from **$1,638,038 thousand** on December 31, 2024, driven by a significant reduction in cash and cash equivalents and a notable decrease in total liabilities primarily due to the repayment of convertible senior notes Condensed Consolidated Balance Sheets (Thousands of Dollars) | Metric (Thousands of Dollars) | June 30, 2025 | December 31, 2024 | | :---------------------------- | :------------ | :---------------- | | **Assets** | | | | Cash and cash equivalents | 154,723 | 367,012 | | Marketable securities | 8,962 | 19,832 | | Accounts receivable, net | 153,125 | 150,540 | | Inventories | 34,171 | 26,748 | | Assets held for sale | 8,956 | — | | Total current assets | 392,553 | 596,019 | | Property and equipment, net | 85,462 | 94,103 | | Intangible assets, net | 301,795 | 339,681 | | Goodwill | 524,143 | 522,766 | | Total assets | 1,393,950 | 1,638,038 | | **Liabilities and Stockholders' Equity** | | | | Accounts payable | 27,492 | 21,607 | | Accrued compensation | 48,557 | 62,443 | | Current convertible senior notes, net | — | 200,777 | | Liabilities held for sale | 456 | — | | Total current liabilities | 100,120 | 301,241 | | Long-term convertible senior notes, net | 341,095 | 340,335 | | Total liabilities | 539,910 | 735,699 | | Total stockholders' equity | 854,040 | 902,339 | | Total liabilities and stockholders' equity | 1,393,950 | 1,638,038 | - As of June 30, 2025, cash and cash equivalents were **$154,723 thousand**, a significant decrease from **$367,012 thousand** on December 31, 2024[10](index=10&type=chunk) - Total current liabilities decreased from **$301,241 thousand** on December 31, 2024, to **$100,120 thousand** on June 30, 2025, primarily due to the repayment of 2025 convertible senior notes[10](index=10&type=chunk) [Condensed Consolidated Statements of Operations](index=6&type=section&id=Condensed%20Consolidated%20Statements%20of%20Operations) For the three and six months ended June 30, 2025, the company experienced revenue growth, but net loss expanded year-over-year due to a significant increase in operating expenses, particularly impairment charges Condensed Consolidated Statements of Operations (Thousands of Dollars) | Metric (Thousands of Dollars) | Three Months Ended June 30, 2025 | Three Months Ended June 30, 2024 | Six Months Ended June 30, 2025 | Six Months Ended June 30, 2024 | | :---------------------------- | :------------------------------- | :------------------------------- | :----------------------------- | :----------------------------- | | Net revenue | 181,330 | 164,502 | 349,365 | 320,742 | | Cost of revenue | 104,072 | 92,008 | 198,861 | 182,779 | | Gross profit | 77,258 | 72,494 | 150,504 | 137,963 | | Total operating expenses | 124,886 | 94,435 | 225,957 | 190,471 | | Operating loss | (47,628) | (21,941) | (75,453) | (52,508) | | Net loss | (45,092) | (18,642) | (71,015) | (45,703) | | Basic net loss per share | (0.35) | (0.15) | (0.56) | (0.36) | | Diluted net loss per share | (0.35) | (0.15) | (0.56) | (0.36) | - For the three months ended June 30, 2025, net revenue increased by **10.2%** to **$181,330 thousand** year-over-year, but net loss expanded from **$18,642 thousand** to **$45,092 thousand**, primarily impacted by **$20,041 thousand** in impairment charges[13](index=13&type=chunk) - For the six months ended June 30, 2025, net revenue increased by **8.9%** to **$349,365 thousand**, and net loss expanded from **$45,703 thousand** to **$71,015 thousand**, also significantly impacted by impairment charges[13](index=13&type=chunk) [Condensed Consolidated Statements of Comprehensive Loss](index=7&type=section&id=Condensed%20Consolidated%20Statements%20of%20Comprehensive%20Loss) For the three and six months ended June 30, 2025, comprehensive loss expanded to **$45,007 thousand** and **$70,780 thousand**, respectively, compared to the prior year, primarily reflecting the increased net loss, partially offset by unrealized gains on marketable securities Condensed Consolidated Statements of Comprehensive Loss (Thousands of Dollars) | Metric (Thousands of Dollars) | Three Months Ended June 30, 2025 | Three Months Ended June 30, 2024 | Six Months Ended June 30, 2025 | Six Months Ended June 30, 2024 | | :---------------------------- | :------------------------------- | :------------------------------- | :----------------------------- | :----------------------------- | | Net loss | (45,092) | (18,642) | (71,015) | (45,703) | | Other comprehensive income (loss): | | | | | | Unrealized gain on marketable securities, net | 85 | 308 | 235 | 652 | | Comprehensive loss | (45,007) | (18,334) | (70,780) | (45,051) | - For the three months ended June 30, 2025, comprehensive loss was **$45,007 thousand**, compared to **$18,334 thousand** in the prior year period[16](index=16&type=chunk) - For the six months ended June 30, 2025, comprehensive loss was **$70,780 thousand**, compared to **$45,051 thousand** in the prior year period[16](index=16&type=chunk) [Condensed Consolidated Statements of Stockholders' Equity](index=8&type=section&id=Condensed%20Consolidated%20Statements%20of%20Stockholders'%20Equity) As of June 30, 2025, total stockholders' equity was **$854,040 thousand**, a decrease from **$902,339 thousand** on December 31, 2024, primarily due to the net loss during the period, partially offset by stock issuances under equity incentive plans and stock-based compensation expense Condensed Consolidated Statements of Stockholders' Equity (Thousands of Dollars) | Metric (Thousands of Dollars) | June 30, 2025 | December 31, 2024 | | :---------------------------- | :------------ | :---------------- | | Total stockholders' equity | 854,040 | 902,339 | | Accumulated deficit | (396,796) | (325,781) | | Additional paid-in capital | 1,250,679 | 1,228,198 | | Accumulated other comprehensive income (loss) | 29 | (206) | - As of June 30, 2025, total stockholders' equity was **$854,040 thousand**, a decrease of **$48,299 thousand** from December 31, 2024[18](index=18&type=chunk) - Accumulated deficit increased from **$325,781 thousand** on December 31, 2024, to **$396,796 thousand** on June 30, 2025, reflecting the net loss during the reporting period[18](index=18&type=chunk) - Additional paid-in capital increased, primarily due to employee stock purchase plan (ESPP) and stock option issuances, and stock-based compensation expense[18](index=18&type=chunk) [Condensed Consolidated Statements of Cash Flows](index=10&type=section&id=Condensed%20Consolidated%20Statements%20of%20Cash%20Flows) For the six months ended June 30, 2025, cash outflows from operating activities decreased, cash outflows from investing activities increased, and cash outflows from financing activities significantly increased, primarily due to the repayment of **$201.3 million** in convertible debt, leading to a notable decrease in cash and cash equivalents at period-end Condensed Consolidated Statements of Cash Flows (Thousands of Dollars) | Metric (Thousands of Dollars) | Six Months Ended June 30, 2025 | Six Months Ended June 30, 2024 | | :---------------------------- | :----------------------------- | :----------------------------- | | Net cash used in operating activities | (4,997) | (12,023) | | Net cash provided by (used in) investing activities | (5,754) | 21,838 | | Net cash provided by (used in) financing activities | (201,484) | 2,782 | | Net change in cash and cash equivalents | (212,289) | 12,597 | | Cash and cash equivalents at end of period | 154,723 | 355,085 | - Cash outflow from operating activities decreased from **$12,023 thousand** in the prior year period to **$4,997 thousand** in the current period[22](index=22&type=chunk) - Cash flow from investing activities shifted from an inflow of **$21,838 thousand** in the prior year period to an outflow of **$5,754 thousand** in the current period, primarily due to decreased proceeds from marketable securities maturities and the Pathline acquisition[22](index=22&type=chunk) - Cash outflow from financing activities was **$201,484 thousand**, compared to an inflow of **$2,782 thousand** in the prior year period, primarily due to the repayment of **$201.3 million** of 2025 convertible senior notes[22](index=22&type=chunk) [Notes to Consolidated Financial Statements](index=11&type=section&id=Notes%20to%20Consolidated%20Financial%20Statements) This section provides detailed notes to the company's consolidated financial statements, covering key information such as the nature of business, significant accounting policies, acquisitions and disposals, fair value measurements, goodwill and intangible assets, debt, stock-based compensation, revenue recognition, restructuring, income taxes, net loss per share, and commitments and contingencies [Note 1. Nature of the Business](index=11&type=section&id=Note%201.%20Nature%20of%20the%20Business) NeoGenomics, Inc. and its subsidiaries provide a broad range of oncology diagnostic testing and consulting services, including technical laboratory services and professional interpretation of laboratory test results by specialized pathologists and oncologists, operating a network of cancer-focused laboratories in the U.S. and U.K. - The company provides oncology diagnostic testing and consulting services, including technical laboratory services and professional interpretations[25](index=25&type=chunk) - The company operates a network of cancer testing laboratories in the U.S. and U.K.[25](index=25&type=chunk) [Note 2. Summary of Significant Accounting Policies](index=11&type=section&id=Note%202.%20Summary%20of%20Significant%20Accounting%20Policies) This note outlines the significant accounting policies followed in preparing the unaudited condensed consolidated financial statements, including the GAAP basis of presentation, consistency with annual report policies, use of estimates, classification of assets held for sale, and recognition of self-insurance liabilities, also discussing recent accounting standard updates pending adoption - Financial statements are prepared in accordance with U.S. Generally Accepted Accounting Principles (GAAP), with all intercompany transactions and balances eliminated[26](index=26&type=chunk) - Management is required to make estimates, judgments, and assumptions when preparing financial statements, which may differ from actual results[30](index=30&type=chunk) - The company became self-insured for employee medical benefits starting January 2025, recording **$1.5 million** in self-insurance liabilities as of June 30, 2025[32](index=32&type=chunk) - The company combined its two primary reportable segments (Clinical Services and Advanced Diagnostics) into a single segment in the fourth quarter of 2024[34](index=34&type=chunk) - FASB issued ASU No. 2024-03 (Expense Disaggregation Disclosures) and ASU No. 2023-09 (Improvements to Income Tax Disclosures), and the company is evaluating their impact on financial statements[36](index=36&type=chunk)[37](index=37&type=chunk) [Note 3. Acquisitions and Disposals](index=12&type=section&id=Note%203.%20Acquisitions%20and%20Disposals) On April 4, 2025, the company completed the acquisition of Pathline LLC for a total purchase consideration of **$8.275 million** to expand its presence in the Northeast, generating **$4.8 million** in goodwill; additionally, the company plans to sell its wholly-owned subsidiary Trapelo Health, LLC, recognizing an **$8.2 million** impairment loss, including **$3.5 million** in goodwill and **$4.7 million** in developed technology - On April 4, 2025, the company acquired Pathline LLC for a total purchase consideration of **$8.275 million** to expand its business and capabilities in the Northeast region[38](index=38&type=chunk)[41](index=41&type=chunk) - The Pathline acquisition generated **$4.8 million** in goodwill, primarily attributable to business synergies, increased market penetration, and expanded service capabilities[42](index=42&type=chunk) - Pathline contributed approximately **$4.7 million** in revenue and **$2.7 million** in net loss during the second quarter of 2025[45](index=45&type=chunk) - The company plans to sell its wholly-owned subsidiary Trapelo Health, LLC, and has classified its assets and liabilities as held for sale[46](index=46&type=chunk)[48](index=48&type=chunk) - Due to the planned sale of Trapelo, the company recognized an **$8.2 million** impairment loss, comprising **$3.5 million** in goodwill and **$4.7 million** in developed technology[49](index=49&type=chunk) [Note 4. Fair Value Measurements](index=14&type=section&id=Note%204.%20Fair%20Value%20Measurements) This note explains how the company measures the fair value of financial assets and liabilities based on a fair value hierarchy (Level 1, Level 2, Level 3); as of June 30, 2025, the company's cash equivalents and available-for-sale marketable securities, totaling **$159,075 thousand**, are primarily measured at Level 1 and Level 2 - Fair value hierarchy is categorized into Level 1 (quoted prices in active markets), Level 2 (observable inputs), and Level 3 (unobservable inputs)[53](index=53&type=chunk)[54](index=54&type=chunk) Fair Value Measurements (Thousands of Dollars) | (Thousands of Dollars) | Level 1 | Level 2 | Level 3 | Total | | :--------------------- | :---------- | :---------- | :------ | :---------- | | **June 30, 2025** | | | | | | Cash equivalents: Money market funds | 150,113 | — | — | 150,113 | | Marketable securities: Municipal bonds | 5,980 | — | — | 5,980 | | Marketable securities: Corporate bonds | — | 2,982 | — | 2,982 | | **Total** | **156,093** | **2,982** | **—** | **159,075** | | **December 31, 2024** | | | | | | Cash equivalents: Money market funds | 364,815 | — | — | 364,815 | | Marketable securities: Municipal bonds | 9,436 | — | — | 9,436 | | Marketable securities: Corporate bonds | — | 10,396 | — | 10,396 | | **Total** | **374,251** | **10,396** | **—** | **384,647** | - As of June 30, 2025, the company's cash equivalents and available-for-sale marketable securities totaled **$159,075 thousand**, primarily measured at Level 1 and Level 2[63](index=63&type=chunk) [Note 5. Goodwill and Intangible Assets](index=16&type=section&id=Note%205.%20Goodwill%20and%20Intangible%20Assets) As of June 30, 2025, total goodwill was **$524,143 thousand**, a slight increase from December 31, 2024, primarily due to **$4.8 million** from the Pathline acquisition, offset by **$3.5 million** in goodwill impairment related to the Trapelo disposal; net intangible assets were **$301,795 thousand**, including **$16.1 million** in impairment losses recognized from the termination of the InVisionFirst®-Lung product portfolio and the Trapelo disposal Goodwill (Thousands of Dollars) | Metric (Thousands of Dollars) | December 31, 2024 | Goodwill from acquisitions | Impairment charges | June 30, 2025 | | :---------------------------- | :---------------- | :------------------------- | :----------------- | :------------ | | Goodwill | 522,766 | 4,840 | (3,463) | 524,143 | - The Pathline acquisition generated **$4.8 million** in goodwill[66](index=66&type=chunk) - Due to the planned disposal of Trapelo, the company recognized a goodwill impairment loss of **$3.5 million**[66](index=66&type=chunk) Intangible Assets (Thousands of Dollars) | Intangible Assets (Thousands of Dollars) | Amortization Period (Years) | Cost | Accumulated Amortization | Net | | :--------------------------------------- | :-------------------------- | :-------- | :----------------------- | :-------- | | Customer relationships | 7 - 15 | 144,301 | 80,410 | 63,891 | | Developed technology | 10 - 15 | 276,825 | 74,487 | 202,338 | | Trademarks | 15 | 30,261 | 8,142 | 22,119 | | Trademarks - indefinite life | — | 13,447 | — | 13,447 | | **Total** | | **464,834** | **163,039** | **301,795** | - The company recognized **$10.5 million** in developed technology losses and **$0.9 million** in trademark losses due to the termination of the InVisionFirst®-Lung product portfolio, and **$4.7 million** in developed technology losses due to the Trapelo disposal[68](index=68&type=chunk)[71](index=71&type=chunk) [Note 6. Debt](index=18&type=section&id=Note%206.%20Debt) This note details the company's convertible senior notes; the 2028 Convertible Notes carry a **0.25%** coupon rate, with a fair value of **$293.3 million** and a net carrying value of **$341.1 million** as of June 30, 2025, while the 2025 Convertible Notes were repaid on May 1, 2025, with a principal of **$201.3 million** - The 2028 Convertible Senior Notes were issued on January 11, 2021, totaling **$345.0 million**, with a **0.25%** coupon rate and maturity on January 15, 2028[72](index=72&type=chunk) - As of June 30, 2025, the estimated fair value (Level 2) of the 2028 Convertible Senior Notes was **$293.3 million**, with a net carrying value of **$341.1 million**[75](index=75&type=chunk) - The 2025 Convertible Senior Notes were repaid on May 1, 2025, with a principal of **$201.3 million** and interest of **$1.3 million**[78](index=78&type=chunk) [Note 7. Stock-Based Compensation](index=19&type=section&id=Note%207.%20Stock-Based%20Compensation) For the six months ended June 30, 2025, the company recognized **$22,968 thousand** in stock-based compensation expense, an increase from the prior year; this note details stock option, restricted stock, and performance share unit (PSU) activity, discloses unrecognized stock-based compensation expense and its amortization period, and reveals **$2.6 million** in additional stock-based compensation expense from accelerated vesting due to executive promotions and departures Stock-Based Compensation Expense (Thousands of Dollars) | Stock-Based Compensation Expense (Thousands of Dollars) | Three Months Ended June 30, 2025 | Three Months Ended June 30, 2024 | Six Months Ended June 30, 2025 | Six Months Ended June 30, 2024 | | :---------------------------------------------------- | :------------------------------- | :------------------------------- | :----------------------------- | :----------------------------- | | Cost of revenue | 302 | 358 | 718 | 753 | | General and administrative expenses | 10,408 | 7,493 | 19,190 | 14,156 | | Research and development expenses | 675 | 237 | 1,272 | 408 | | Sales and marketing expenses | 830 | 753 | 1,788 | 1,298 | | **Total stock-based compensation expense** | **12,215** | **8,841** | **22,968** | **16,615** | - As of June 30, 2025, unrecognized stock-based compensation expense related to stock options was approximately **$19.4 million**, to be recognized over approximately **1.6 years**[83](index=83&type=chunk) - As of June 30, 2025, unrecognized stock-based compensation expense related to restricted stock was approximately **$22.5 million**, to be recognized over approximately **1.4 years**[84](index=84&type=chunk) - As of June 30, 2025, unrecognized stock-based compensation expense related to non-vested PSUs was approximately **$5.5 million**, to be recognized over approximately **1.4 years**[86](index=86&type=chunk) - In the second quarter of 2025, **$2.6 million** in stock-based compensation expense was recognized due to accelerated vesting from executive promotions and departures[87](index=87&type=chunk) [Note 8. Revenue Recognition](index=21&type=section&id=Note%208.%20Revenue%20Recognition) The company primarily recognizes revenue from oncology diagnostic testing and consulting services, pharmaceutical development services, and oncology data solutions; clinical service revenue is recognized upon service completion and delivery of results to physicians, pharmaceutical development service revenue is typically recognized per unit of service or over time, and oncology data solution revenue is recognized upon data delivery or over time, with this note also providing a breakdown of revenue by customer type - Clinical service revenue is recognized when services are completed and results are delivered to physicians[90](index=90&type=chunk) - Pharmaceutical development service revenue is typically recognized per unit of service or over time[91](index=91&type=chunk) - Oncology data solution revenue is recognized upon delivery for retrospective data or over time for prospective data[92](index=92&type=chunk) Net Revenue by Category (Thousands of Dollars) | Net Revenue by Category (Thousands of Dollars) | Three Months Ended June 30, 2025 | Three Months Ended June 30, 2024 | Six Months Ended June 30, 2025 | Six Months Ended June 30, 2024 | | :--------------------------------------------- | :------------------------------- | :------------------------------- | :----------------------------- | :----------------------------- | | Direct bill to clients | 131,157 | 118,305 | 253,195 | 230,493 | | Commercial insurance | 28,766 | 24,843 | 53,623 | 48,447 | | Medicare and other government | 21,387 | 21,197 | 42,488 | 41,566 | | Patient pay | 20 | 157 | 59 | 236 | | **Total net revenue** | **181,330** | **164,502** | **349,365** | **320,742** | [Note 9. Restructuring](index=22&type=section&id=Note%209.%20Restructuring) The company completed a restructuring plan in 2024 aimed at improving execution and organizational efficiency; for the three and six months ended June 30, 2025, no restructuring charges were incurred, compared to **$1.5 million** and **$3.9 million** in the respective prior year periods - The company completed a restructuring plan in 2024, aimed at improving execution and organizational efficiency[99](index=99&type=chunk)[100](index=100&type=chunk) - For the three and six months ended June 30, 2025, the company incurred no restructuring charges[100](index=100&type=chunk) - As of December 31, 2024, current liabilities related to the company's restructuring plan were **$0.9 million**, becoming immaterial by June 30, 2025[101](index=101&type=chunk) [Note 10. Income Taxes](index=22&type=section&id=Note%2010.%20Income%20Taxes) The company estimates its annual effective tax rate based on projected pre-tax results; as of June 30, 2025, both U.S. and U.K. operations were in a three-year cumulative loss position, with U.S. operations incurring tax expense due to valuation allowances, while U.K. operations generated a tax benefit from deferred tax liability reversals related to intangible asset impairment losses, exceeding U.S. tax expense; additionally, the U.S. 'One Big Beautiful Bill Act' signed on July 4, 2025, is not expected to materially impact the company's financial statements - As of June 30, 2025, the company's U.S. and U.K. operations were both in a three-year cumulative loss position[104](index=104&type=chunk)[105](index=105&type=chunk) - U.S. operations incurred tax expense due to valuation allowances against deferred tax assets[104](index=104&type=chunk) - U.K. operations generated a tax benefit from deferred tax liability reversals related to intangible asset impairment losses, which exceeded the U.S. tax expense[108](index=108&type=chunk) - The 'One Big Beautiful Bill Act' signed on July 4, 2025, is not expected to materially impact the company's financial statements[109](index=109&type=chunk) [Note 11. Net Loss Per Share](index=23&type=section&id=Note%2011.%20Net%20Loss%20Per%20Share) For the three and six months ended June 30, 2025, basic and diluted net loss per share were **$0.35** and **$0.56**, respectively, an expansion from the prior year; due to the company's net loss position, all potentially dilutive shares, including stock options, restricted stock, 2025 and 2028 convertible notes, and PSUs, were excluded from diluted net loss per share calculations as they were anti-dilutive Net Loss Per Share (Thousands of Dollars, except per share data) | Metric (Thousands of Dollars, except per share data) | Three Months Ended June 30, 2025 | Three Months Ended June 30, 2024 | Six Months Ended June 30, 2025 | Six Months Ended June 30, 2024 | | :--------------------------------------------------- | :------------------------------- | :------------------------------- | :----------------------------- | :----------------------------- | | Net loss | (45,092) | (18,642) | (71,015) | (45,703) | | Basic weighted-average common shares outstanding | 127,949 | 126,405 | 127,664 | 126,257 | | Diluted weighted-average common shares outstanding | 127,949 | 126,405 | 127,664 | 126,257 | | Basic net loss per share | (0.35) | (0.15) | (0.56) | (0.36) | | Diluted net loss per share | (0.35) | (0.15) | (0.56) | (0.36) | - Due to the company's net loss position, potentially dilutive shares such as stock options, restricted stock, 2025 and 2028 convertible notes, and PSUs were excluded from diluted net loss per share calculations as they were anti-dilutive[111](index=111&type=chunk) [Note 12. Commitments and Contingencies](index=24&type=section&id=Note%2012.%20Commitments%20and%20Contingencies) The company faces multiple legal proceedings and regulatory investigations, including ongoing patent infringement litigation by Natera involving InVisionFirst®-Lung and RaDaR® tests, where RaDaR® 1.0 was settled with a permanent injunction but RaDaR® 1.1 litigation is pending; additionally, the company faces shareholder class action and derivative lawsuits, and regulatory investigations related to federal healthcare law compliance, for which **$11.2 million** has been accrued - Natera, Inc. filed patent infringement lawsuits against Inivata Limited and its subsidiaries, involving InVisionFirst®-Lung and RaDaR® tests[115](index=115&type=chunk) - A partial settlement and permanent injunction were issued for the RaDaR® 1.0 test, but litigation regarding RaDaR® 1.1 and the '454 and '596 patents is expected to proceed to trial in October 2025[116](index=116&type=chunk) - The company faces a shareholder class action lawsuit (Goldenberg Matter) and multiple shareholder derivative lawsuits alleging material misstatements and/or omissions in its public disclosures[116](index=116&type=chunk) - The company is cooperating with investigations by the U.S. Department of Health and Human Services Office of Inspector General (OIG) and the Department of Justice (DOJ) into the compliance of certain consulting and service agreements with federal healthcare laws and regulations, for which **$11.2 million** has been accrued[117](index=117&type=chunk)[119](index=119&type=chunk) [Note 13. Segment Information](index=25&type=section&id=Note%2013.%20Segment%20Information) In the fourth quarter of 2024, the company combined its former Clinical Services and Advanced Diagnostics reportable segments into a single segment to streamline operations and enhance service offerings; the CEO, as Chief Operating Decision Maker (CODM), uses net loss from the consolidated statements of operations to monitor budget versus actual results, assess profitability, and allocate resources - The company combined its two primary reportable segments (Clinical Services and Advanced Diagnostics) into a single segment in the fourth quarter of 2024[120](index=120&type=chunk) - The Chief Executive Officer, as Chief Operating Decision Maker (CODM), uses net loss from the consolidated statements of operations to monitor budget versus actual results, assess profitability, and allocate resources[121](index=121&type=chunk) Segment Information (Thousands of Dollars) | Segment Information (Thousands of Dollars) | Three Months Ended June 30, 2025 | Three Months Ended June 30, 2024 | Six Months Ended June 30, 2025 | Six Months Ended June 30, 2024 | | :----------------------------------------- | :------------------------------- | :------------------------------- | :----------------------------- | :----------------------------- | | Net revenue | 181,330 | 164,502 | 349,365 | 320,742 | | Operating loss | (47,628) | (21,941) | (75,453) | (52,508) | | Net loss | (45,092) | (18,642) | (71,015) | (45,703) | [Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations](index=26&type=section&id=Item%202.%20Management's%20Discussion%20and%20Analysis%20of%20Financial%20Condition%20and%20Results%20of%20Operations) This section provides management's detailed discussion and analysis of the company's financial condition and operating results, covering an overview, strategic focus, competitive strengths, seasonality, recent regulatory changes, and a comparison of financial performance for the three and six months ended June 30, 2025; the report indicates net revenue growth but expanded net loss due to increased impairment charges and operating costs, also discussing non-GAAP financial measures, liquidity, and capital resources [Introduction](index=26&type=section&id=Introduction) This introduction emphasizes that this discussion and analysis should be read in conjunction with the unaudited consolidated financial statements and their notes, and cautions that forward-looking statements contained herein are subject to risks and uncertainties that could cause actual results to differ materially from expectations - This discussion and analysis should be read in conjunction with the unaudited consolidated financial statements and their notes[124](index=124&type=chunk) - The report contains forward-looking statements, involving risks and uncertainties that could cause actual results to differ materially from expectations[124](index=124&type=chunk) [Overview](index=26&type=section&id=Overview) NeoGenomics provides a broad range of oncology diagnostic testing and consulting services, including technical laboratory services and professional interpretations, operating a network of cancer testing laboratories in the U.S. and U.K.; the company's mission is to save lives by improving patient care, with a vision to be a global leader in cancer testing, information, and decision support - The company provides a broad range of oncology diagnostic testing and consulting services, including technical laboratory services and professional interpretations[125](index=125&type=chunk) - The company operates a network of cancer testing laboratories in the U.S. and U.K.[125](index=125&type=chunk) - The company offers various testing services, including cytogenetics, fluorescence in situ hybridization (FISH), flow cytometry, immunohistochemistry (IHC) and digital imaging, molecular testing, and morphological analysis[126](index=126&type=chunk) [Reportable Segments](index=27&type=section&id=Reportable%20Segments) In 2024, the company streamlined its operational approach by combining its former Clinical Services and Advanced Diagnostics segments into a single reportable segment, aiming to optimize operations and enhance service to diverse client groups, including community pathology and oncology practices, hospital pathology laboratories, reference laboratories, academic centers, and pharmaceutical companies - The company combined its former Clinical Services and Advanced Diagnostics segments into a single reportable segment in 2024[129](index=129&type=chunk) - This decision aims to streamline operations and enhance service to diverse client groups, including community pathology and oncology practices, hospital pathology laboratories, reference laboratories, academic centers, and pharmaceutical companies[129](index=129&type=chunk) [Revenue Streams](index=27&type=section&id=Revenue%20Streams) The company's single operating segment encompasses a broad range of services, including clinical cancer testing, interpretation and consulting, molecular and NGS testing, comprehensive technical and professional services, clinical trials and research, validation laboratory services, and oncology data solutions, all designed to support pathologists and oncologists and provide drug development support to pharmaceutical companies - The company's revenue streams include clinical cancer testing, interpretation and consulting services, molecular and NGS testing, comprehensive technical and professional services, clinical trials and research, validation laboratory services, and oncology data solutions[134](index=134&type=chunk) - The company offers Technical Component (TC) and Professional Component (PC) services, enabling clients to participate in the diagnostic process[130](index=130&type=chunk)[131](index=131&type=chunk) - The company is a leading provider of hematologic oncology diagnostic testing, including molecular and NGS testing, and a key provider of solid tumor NGS testing solutions[133](index=133&type=chunk) - The company enhanced its oncology liquid biopsy technology through the acquisition of Inivata, including RaDaR®, used to detect residual disease and recurrence in solid tumor patients[136](index=136&type=chunk) - Pharmaceutical development services support pharmaceutical companies' drug development programs from biomarker discovery to commercialization, including clinical trials, research, and companion diagnostic development[137](index=137&type=chunk) [Strategic Focus](index=28&type=section&id=Strategic%20Focus) By streamlining segments, the company aims to provide seamlessly integrated services and leverage its oncology and molecular diagnostics expertise to more effectively support clinical and pharmaceutical clients; strategic priorities for 2025 include profitably growing the core business, accelerating innovation, driving value creation, and elevating people and culture - By streamlining segments, the company aims to provide seamlessly integrated services and leverage its oncology and molecular diagnostics expertise to more effectively support clinical and pharmaceutical clients[139](index=139&type=chunk) - Key focus areas for 2025 include: profitably growing the core business (accelerating volume growth, accelerating oncologist partnerships, executing pharmaceutical client strategy), accelerating innovation (delivering product roadmap, successful and timely product launches, driving data solution productization and sales excellence), driving value creation (improving operating efficiency and gross margins, transforming the digital ecosystem, achieving positive cash flow from operations), and elevating people and culture (enhancing Neo culture, expanding scientific, medical, and product capabilities)[140](index=140&type=chunk)[141](index=141&type=chunk) [Competitive Strengths](index=28&type=section&id=Competitive%20Strengths) The company's competitive strengths include superior testing technology and instrumentation, laboratory information systems, client education programs, and domestic and international business presence; additionally, the company enhances its market competitiveness through continuous improvement in test result turnaround times, offering a comprehensive oncology test menu, and maintaining a dedicated national direct sales force - The company's competitive strengths include superior testing technology and instrumentation, laboratory information systems, client education programs, and domestic and international business presence[140](index=140&type=chunk) - The company continuously focuses on improving test result turnaround times to ensure physicians receive timely information for treatment initiation[142](index=142&type=chunk) - The company offers comprehensive technical and professional interpretation services, meeting client needs across various testing modalities[143](index=143&type=chunk) - The company maintains a dedicated national direct sales force, extensively trained in cancer genomic testing and consultative selling skills, to meet client needs[145](index=145&type=chunk) [Seasonality and Other Factors Affecting the Business](index=29&type=section&id=Seasonality%20and%20Other%20Factors%20Affecting%20the%20Business) The company's clinical testing volumes are subject to seasonality, typically declining during summer, year-end holidays, and severe weather; pharmaceutical development service volumes depend on contract terms and clinical trial patient enrollment rates; additionally, product launches, business investments, and annual resets of patient deductibles impact revenue, with higher revenue typically in the third and fourth quarters; changes in tariff policies may also affect supply chains and profitability - Clinical testing volumes typically experience a modest decline during summer, year-end holidays, and other major holidays, and are affected by extreme adverse weather conditions[146](index=146&type=chunk) - Pharmaceutical development service volumes are uncertain, influenced by contract terms and the pace of clinical trial patient enrollment[147](index=147&type=chunk) - Due to factors such as product launches, business investments, and annual resets of patient deductibles, the company's revenue is typically higher in the third and fourth quarters[148](index=148&type=chunk) - Changes in tariff policies could lead to supply chain challenges and customer demand uncertainty, impacting net sales and profitability[149](index=149&type=chunk) [Laboratory Developed Tests (LDTs)](index=30&type=section&id=Laboratory%20Developed%20Tests%20(LDTs)) The U.S. Food and Drug Administration (FDA) previously issued a final rule to phase out its general enforcement discretion over Laboratory Developed Tests (LDTs); however, on March 31, 2025, the U.S. District Court for the Eastern District of Texas vacated the FDA's final rule, ruling that the FDA exceeded its statutory authority, thus LDTs will continue to be regulated under the existing framework - The FDA previously issued a final rule to phase out its general enforcement discretion over LDTs[150](index=150&type=chunk) - On March 31, 2025, the U.S. District Court for the Eastern District of Texas vacated the FDA's final rule, ruling that the FDA exceeded its statutory authority[151](index=151&type=chunk) - LDTs will continue to be regulated under the existing framework[151](index=151&type=chunk) [One Big Beautiful Bill Act of 2025](index=30&type=section&id=One%20Big%20Beautiful%20Bill%20Act%20of%202025) On July 4, 2025, the U.S. enacted the 'One Big Beautiful Bill Act' (OBBBA), which made significant changes to federal tax law and other regulatory provisions; the company is evaluating the impact of OBBBA on its business, prospects, and financial statements - On July 4, 2025, the U.S. enacted the 'One Big Beautiful Bill Act' (OBBBA), which made significant changes to federal tax law and other regulatory provisions[152](index=152&type=chunk) - The company is evaluating the impact of OBBBA on its business, prospects, and financial statements[152](index=152&type=chunk) [Results of Operations for the Three and Six Months Ended June 30, 2025 as Compared to the Three and Six Months Ended June 30, 2024](index=30&type=section&id=Results%20of%20Operations%20for%20the%20Three%20and%20Six%20Months%20Ended%20June%2030%2C%202025%20as%20Compared%20to%20the%20Three%20and%20Six%20Months%20Ended%20June%2030%2C%202024) This section details the company's operating results for the three and six months ended June 30, 2025, compared to the prior year; despite net revenue growth, operating and net losses significantly expanded due to increased cost of revenue, general and administrative expenses, research and development expenses, sales and marketing expenses, and notably, impairment charges; interest income decreased, while interest expense declined due to the repayment of 2025 convertible notes [Revenue](index=30&type=section&id=Revenue) For the three and six months ended June 30, 2025, net revenue grew by **10.2%** and **8.9%**, respectively, primarily driven by increased testing volumes, higher average unit prices from strategic reimbursement initiatives, and revenue contributions from the Pathline acquisition, partially offset by a decline in non-clinical revenue and an unfavorable test mix Revenue (Thousands of Dollars) | Revenue (Thousands of Dollars) | Three Months Ended June 30, 2025 | Three Months Ended June 30, 2024 | Change | Percentage Change | | :----------------------------- | :------------------------------- | :------------------------------- | :----- | :---------------- | | Revenue | 181,330 | 164,502 | 16,828 | 10.2 % | | Revenue (Thousands of Dollars) | Six Months Ended June 30, 2025 | Six Months Ended June 30, 2024 | Change | Percentage Change | | :----------------------------- | :----------------------------- | :----------------------------- | :----- | :---------------- | | Revenue | 349,365 | 320,742 | 28,623 | 8.9 % | - Revenue growth primarily reflects increased testing volumes, higher average unit prices from strategic reimbursement initiatives, and revenue contributions from the Pathline acquisition[153](index=153&type=chunk) - Revenue growth was partially offset by a decline in non-clinical revenue due to macro clinical trial trends in the pharmaceutical industry and an unfavorable test mix[153](index=153&type=chunk) [Cost of Revenue and Gross Profit](index=31&type=section&id=Cost%20of%20Revenue%20and%20Gross%20Profit) For the three and six months ended June 30, 2025, cost of revenue increased by **13.1%** and **8.8%**, respectively, primarily due to higher compensation and benefits, supplies, and postage and shipping costs; gross profit margin decreased by **1.5 percentage points** to **42.6%** for the three-month period and slightly increased by **0.1 percentage point** to **43.1%** for the six-month period, reflecting the trade-off between revenue growth and cost increases Cost of Revenue and Gross Profit (Thousands of Dollars) | Metric (Thousands of Dollars) | Three Months Ended June 30, 2025 | Three Months Ended June 30, 2024 | Percentage Change | | :---------------------------- | :------------------------------- | :------------------------------- | :---------------- | | Cost of revenue | 104,072 | 92,008 | 13.1 % | | Cost of revenue as a percentage of revenue | 57.4% | 55.9% | | | Gross profit | 77,258 | 72,494 | 6.6 % | | Gross profit margin | 42.6% | 44.1% | | | Metric (Thousands of Dollars) | Six Months Ended June 30, 2025 | Six Months Ended June 30, 2024 | Percentage Change | | :---------------------------- | :----------------------------- | :----------------------------- | :---------------- | | Cost of revenue | 198,861 | 182,779 | 8.8 % | | Cost of revenue as a percentage of revenue | 56.9% | 57.0% | | | Gross profit | 150,504 | 137,963 | 9.1 % | | Gross profit margin | 43.1% | 43.0% | | - The increase in cost of revenue was primarily due to higher compensation and benefits costs of **$7.3 million** (three months) and **$10.1 million** (six months), increased supplies expense of **$3.9 million** (three months) and **$5.7 million** (six months), and higher postage and shipping costs[157](index=157&type=chunk)[158](index=158&type=chunk) - Gross profit margin decreased by **1.5 percentage points** to **42.6%** for the three-month period and slightly increased by **0.1 percentage point** to **43.1%** for the six-month period[159](index=159&type=chunk) [General and Administrative Expenses](index=31&type=section&id=General%20and%20Administrative%20Expenses) For the three and six months ended June 30, 2025, general and administrative expenses increased by **13.3%** and **8.4%**, respectively, primarily driven by higher software and software development costs, compensation and benefits, and professional service fees, partially offset by reduced equipment maintenance and facility-related expenses General and Administrative Expenses (Thousands of Dollars) | General and Administrative Expenses (Thousands of Dollars) | Three Months Ended June 30, 2025 | Three Months Ended June 30, 2024 | Change | Percentage Change | | :------------------------------------------------------- | :------------------------------- | :------------------------------- | :----- | :---------------- | | General and administrative expenses | 71,747 | 63,328 | 8,419 | 13.3 % | | As a percentage of revenue | 39.6 % | 38.5 % | | | | General and Administrative Expenses (Thousands of Dollars) | Six Months Ended June 30, 2025 | Six Months Ended June 30, 2024 | Change | Percentage Change | | :------------------------------------------------------- | :----------------------------- | :----------------------------- | :----- | :---------------- | | General and administrative expenses | 139,954 | 129,125 | 10,829 | 8.4 % | | As a percentage of revenue | 40.1 % | 40.3 % | | | - For the three-month period, general and administrative expenses increased by **$8.4 million**, primarily due to a **$2.7 million** increase in software and software development costs, a **$2.4 million** increase in compensation and benefits costs, and a **$2.2 million** increase in professional service fees[161](index=161&type=chunk) - For the six-month period, general and administrative expenses increased by **$10.8 million**, primarily due to a **$6.9 million** increase in compensation and benefits costs, a **$4.2 million** increase in software and software development costs, and a **$1.7 million** increase in transaction costs[162](index=162&type=chunk) [Research and Development Expenses](index=31&type=section&id=Research%20and%20Development%20Expenses) For the three and six months ended June 30, 2025, research and development expenses increased by **14.4%** and **23.8%**, respectively, primarily due to reduced U.K. R&D tax credits, higher compensation and benefits costs, increased supplies expense, and higher professional service fees; the company anticipates continued increases in future R&D expenditures Research and Development Expenses (Thousands of Dollars) | Research and Development Expenses (Thousands of Dollars) | Three Months Ended June 30, 2025 | Three Months Ended June 30, 2024 | Change | Percentage Change | | :----------------------------------------------------- | :------------------------------- | :------------------------------- | :----- | :---------------- | | Research and development expenses | 9,023 | 7,886 | 1,137 | 14.4 % | | As a percentage of revenue | 5.0 % | 4.8 % | | | | Research and Development Expenses (Thousands of Dollars) | Six Months Ended June 30, 2025 | Six Months Ended June 30, 2024 | Change | Percentage Change | | :----------------------------------------------------- | :----------------------------- | :----------------------------- | :----- | :---------------- | | Research and development expenses | 19,204 | 15,506 | 3,698 | 23.8 % | | As a percentage of revenue | 5.5 % | 4.8 % | | | - For the three-month period, research and development expenses increased by **$1.1 million**, primarily due to a **$0.6 million** reduction in U.K. R&D tax credits, a **$0.4 million** increase in compensation and benefits costs, and a **$0.3 million** increase in supplies expense[164](index=164&type=chunk) - For the six-month period, research and development expenses increased by **$3.7 million**, primarily due to a **$1.2 million** increase in compensation and benefits costs, a **$1.0 million** reduction in U.K. R&D tax credits, a **$0.6 million** increase in supplies expense, and a **$0.5 million** increase in professional service fees[165](index=165&type=chunk) - The company anticipates increased future R&D expenditures to support innovation initiatives and new product launches[166](index=166&type=chunk) [Sales and Marketing Expenses](index=32&type=section&id=Sales%20and%20Marketing%20Expenses) For the three and six months ended June 30, 2025, sales and marketing expenses increased by **11.1%** and **11.6%**, respectively, primarily due to higher compensation and benefits costs from sales team expansion, increased professional service fees, and travel expenses; the company expects future sales commission expenses to rise with sales team expansion and new business growth Sales and Marketing Expenses (Thousands of Dollars) | Sales and Marketing Expenses (Thousands of Dollars) | Three Months Ended June 30, 2025 | Three Months Ended June 30, 2024 | Change | Percentage Change | | :-------------------------------------------------- | :------------------------------- | :------------------------------- | :----- | :---------------- | | Sales and marketing expenses | 24,075 | 21,677 | 2,398 | 11.1 % | | As a percentage of revenue | 13.3 % | 13.2 % | | | | Sales and Marketing Expenses (Thousands of Dollars) | Six Months Ended June 30, 2025 | Six Months Ended June 30, 2024 | Change | Percentage Change | | :-------------------------------------------------- | :----------------------------- | :----------------------------- | :----- | :---------------- | | Sales and marketing expenses | 46,758 | 41,898 | 4,860 | 11.6 % | | As a percentage of revenue | 13.4 % | 13.1 % | | | - For the three-month period, sales and marketing expenses increased by **$2.4 million**, primarily due to a **$1.7 million** increase in compensation and benefits costs from sales team expansion[167](index=167&type=chunk) - For the six-month period, sales and marketing expenses increased by **$4.9 million**, primarily due to a **$3.0 million** increase in compensation and benefits costs from sales team expansion[168](index=168&type=chunk) - The company anticipates increased future sales commission expenses with sales team expansion and new business growth[169](index=169&type=chunk) [Restructuring charges](index=32&type=section&id=Restructuring%20charges) For the three and six months ended June 30, 2025, the company incurred no restructuring charges, compared to **$1.5 million** and **$3.9 million** in the respective prior year periods, a decrease attributed to the completion of restructuring activities by December 31, 2024 Restructuring Charges (Thousands of Dollars) | Restructuring Charges (Thousands of Dollars) | Three Months Ended June 30, 2025 | Three Months Ended June 30, 2024 | Change | Percentage Change | | :------------------------------------------- | :------------------------------- | :------------------------------- | :-------- | :---------------- | | Restructuring charges | — | 1,544 | (1,544) | (100.0)% | | Restructuring Charges (Thousands of Dollars) | Six Months Ended June 30, 2025 | Six Months Ended June 30, 2024 | Change | Percentage Change | | :------------------------------------------- | :----------------------------- | :----------------------------- | :-------- | :---------------- | | Restructuring charges | — | 3,942 | (3,942) | (100.0)% | - Restructuring charges decreased by **100%** for both the three and six months in 2025, as restructuring activities were completed by December 31, 2024[171](index=171&type=chunk) [Impairment charges](index=32&type=section&id=Impairment%20charges) For the three and six months ended June 30, 2025, impairment charges increased by **$20.0 million** in both periods, compared to zero in the prior year, primarily comprising **$11.4 million** for InVisionFirst®-Lung intangible assets, **$8.2 million** for the disposal group held for sale, and **$0.4 million** for InVisionFirst®-Lung inventory write-offs Impairment Charges (Thousands of Dollars) | Impairment Charges (Thousands of Dollars) | Three Months Ended June 30, 2025 | Three Months Ended June 30, 2024 | Change | Percentage Change | | :---------------------------------------- | :------------------------------- | :------------------------------- | :----- | :---------------- | | Impairment charges | 20,041 | — | 20,041 | Not Applicable | | Impairment Charges (Thousands of Dollars) | Six Months Ended June 30, 2025 | Six Months Ended June 30, 2024 | Change | Percentage Change | | :---------------------------------------- | :----------------------------- | :----------------------------- | :----- | :---------------- | | Impairment charges | 20,041 | — | 20,041 | Not Applicable | - Impairment charges increased by **$20.0 million**, primarily comprising **$11.4 million** for InVisionFirst®-Lung intangible assets, **$8.2 million** for the disposal group held for sale, and **$0.4 million** for InVisionFirst®-Lung inventory write-offs[173](index=173&type=chunk) [Interest Income](index=32&type=section&id=Interest%20Income) For the three and six months ended June 30, 2025, interest income decreased by **50.7%** and **36.5%**, respectively, primarily due to a lower average cash balance invested and a reduced interest rate environment Interest Income (Thousands of Dollars) | Interest Income (Thousands of Dollars) | Three Months Ended June 30, 2025 | Three Months Ended June 30, 2024 | Change | Percentage Change | | :------------------------------------- | :------------------------------- | :------------------------------- | :----- | :---------------- | | Interest income | (2,263) | (4,592) | 2,329 | (50.7)% | | Interest Income (Thousands of Dollars) | Six Months Ended June 30, 2025 | Six Months Ended June 30, 2024 | Change | Percentage Change | | :------------------------------------- | :----------------------------- | :----------------------------- | :----- | :---------------- | | Interest income | (5,984) | (9,426) | 3,442 | (36.5)% | - The decrease in interest income was primarily due to a lower average cash balance invested and a reduced interest rate environment[176](index=176&type=chunk) [Interest Expense](index=33&type=section&id=Interest%20Expense) For the three and six months ended June 30, 2025, interest expense decreased by **44.0%** and **23.9%**, respectively, primarily attributable to the company's repayment of the 2025 convertible senior notes in the second quarter of 2025 Interest Expense (Thousands of Dollars) | Interest Expense (Thousands of Dollars) | Three Months Ended June 30, 2025 | Three Months Ended June 30, 2024 | Change | Percentage Change | | :-------------------------------------- | :------------------------------- | :------------------------------- | :----- | :---------------- | | Interest expense | 933 | 1,666 | (733) | (44.0)% | | Interest Expense (Thousands of Dollars) | Six Months Ended June 30, 2025 | Six Months Ended June 30, 2024 | Change | Percentage Change | | :-------------------------------------- | :----------------------------- | :----------------------------- | :----- | :---------------- | | Interest expense | 2,551 | 3,351 | (800) | (23.9)% | - The decrease in

[Executive Summary & Highlights](index=1&type=section&id=Executive%20Summary%20%26%20Highlights) NeoGenomics saw strong Q2 2025 revenue growth from clinical volumes, but net loss surged due to impairment charges, while strategically expanding [Second Quarter 2025 Financial Highlights](index=1&type=section&id=Second%20Quarter%202025%20Financial%20Highlights) NeoGenomics saw Q2 2025 revenue rise 10% to $181 million, driven by clinical growth, but net loss increased significantly due to impairment charges Second Quarter 2025 Key Financial Highlights | Metric | Q2 2025 (Millions) | Q2 2024 (Millions) | Change (%) | | :--------------------- | :------------------ | :------------------ | :--------- | | Consolidated Revenue | $181 | $164.5 | 10% | | Net Loss | $(45) | $(19) | 142% | | Adjusted EBITDA | $10.7 | $10.9 | -1.8% | - Consolidated gross profit increased by **7% to $77 million**, with an Adjusted Gross Profit Margin of **45%**[4](index=4&type=chunk) - Operating expenses rose by **32% to $125 million**, largely due to **$20 million in impairment charges** related to the planned sale of Trapelo and the InVisionFirst®-Lung intangible asset, as well as **$4.4 million in higher compensation and benefit costs**[4](index=4&type=chunk)[6](index=6&type=chunk) [Operational & Strategic Overview](index=1&type=section&id=Operational%20%26%20Strategic%20Overview) Clinical business grew strongly, particularly NGS, despite pharma revenue pressure and PanTracer™ launch delays, with future focus on R&D and partnerships - Clinical revenue increased by **16%** (**13% excluding Pathline**), driven by sequential improvement in Average Unit Price (AUP), record volumes, and **23% growth in NGS**[1](index=1&type=chunk)[2](index=2&type=chunk) - Challenges included continuing pressure in pharma revenue and a delay in the commercial launch of PanTracer™ Liquid Biopsy, impacting expected NGS revenue[2](index=2&type=chunk) - Future strategic initiatives include enhancing R&D for new therapy selection and next-gen MRD products, preparing for the commercial launch of PanTracer Liquid Biopsy, growing the sales team, increasing efficiencies, and pursuing partnerships[2](index=2&type=chunk) [Second-Quarter Financial Results](index=5&type=section&id=Second-Quarter%20Financial%20Results) Q2 2025 financial results show increased revenue but a higher net loss due to impairment charges, alongside reduced cash and convertible debt repayment [Condensed Consolidated Balance Sheets](index=5&type=section&id=Condensed%20Consolidated%20Balance%20Sheets) Total assets decreased by June 30, 2025, mainly from reduced cash, while total liabilities also fell due to convertible senior notes repayment Key Balance Sheet Items (in thousands) | Item | June 30, 2025 (thousands) | December 31, 2024 (thousands) | | :------------------------ | :------------------------ | :---------------------------- | | Cash and cash equivalents | $154,723 | $367,012 | | Total current assets | $392,553 | $596,019 | | Total assets | $1,393,950 | $1,638,038 | | Total current liabilities | $100,120 | $301,241 | | Convertible senior notes | $341,095 | $340,335 | | Total liabilities | $539,910 | $735,699 | | Total stockholders' equity| $854,040 | $902,339 | - Assets held for sale increased to **$8,956 thousand** as of June 30, 2025, from zero at year-end 2024[19](index=19&type=chunk) - The current portion of convertible senior notes decreased from **$200,777 thousand** to zero, indicating a significant repayment[19](index=19&type=chunk) [Condensed Consolidated Statements of Operations](index=6&type=section&id=Condensed%20Consolidated%20Statements%20of%20Operations) Q2 2025 net revenue increased 10.2% to $181.3 million, but higher operating expenses, mainly impairment charges, led to a significant net loss Q2 2025 vs Q2 2024 Statements of Operations (in thousands) | Metric | Q2 2025 (thousands) | Q2 2024 (thousands) | Change (%) | | :---------------------- | :------------------ | :------------------ | :--------- | | Net Revenue | $181,330 | $164,502 | 10.2% | | Cost of Revenue | $104,072 | $92,008 | 13.1% | | Gross Profit | $77,258 | $72,494 | 6.6% | | Total Operating Expenses| $124,886 | $94,435 | 32.2% | | Loss From Operations | $(47,628) | $(21,941) | 117.1% | | Net Loss | $(45,092) | $(18,642) | 142.0% | | Basic EPS | $(0.35) | $(0.15) | 133.3% | - Impairment charges of **$20,041 thousand** were recorded in Q2 2025, significantly contributing to the increase in operating expenses and net loss, compared to no such charges in Q2 2024[21](index=21&type=chunk) [Condensed Consolidated Statements of Cash Flows](index=7&type=section&id=Condensed%20Consolidated%20Statements%20of%20Cash%20Flows) YTD June 30, 2025, experienced net cash outflows across all activities, primarily from convertible debt repayment, leading to a substantial cash decrease YTD June 30, 2025 vs 2024 Cash Flows (in thousands) | Cash Flow Activity | YTD June 30, 2025 (thousands) | YTD June 30, 2024 (thousands) | | :----------------------------- | :---------------------------- | :---------------------------- | | Net cash used in operating activities | $(4,997) | $(12,023) | | Net cash (used in) provided by investing activities | $(5,754) | $21,838 | | Net cash (used in) provided by financing activities | $(201,484) | $2,782 | | Net change in cash and cash equivalents | $(212,289) | $12,597 | | Cash and cash equivalents, end of period | $154,723 | $355,085 | - The significant cash outflow from financing activities was primarily driven by the repayment of **$201,250 thousand in convertible debt**[23](index=23&type=chunk) - Investing activities included **$11,060 thousand** from maturities of marketable securities and **$10,823 thousand** for purchases of property and equipment, along with **$5,991 thousand** for business acquisition (net of cash acquired)[23](index=23&type=chunk) [Business Developments](index=3&type=section&id=Business%20Developments) NeoGenomics expanded its Northeastern US presence and capabilities through the strategic acquisition of Pathline, LLC in April 2025 [Pathline, LLC Acquisition](index=3&type=section&id=Pathline%2C%20LLC%20Acquisition) NeoGenomics completed the acquisition of Pathline, LLC in April 2025, expanding its presence and capabilities in the Northeastern US - The acquisition of Pathline, LLC, a CLIA/CAP/NYS-certified laboratory, was completed on **April 4, 2025**[9](index=9&type=chunk) - The purchase price included an initial cash consideration of **$8.0 million** and contingent consideration of **$1.0 million**[9](index=9&type=chunk) - This acquisition aligns with NeoGenomics' strategic objective to expand its presence, capabilities, and offerings in the Northeastern United States[9](index=9&type=chunk) [Financial Guidance](index=3&type=section&id=Financial%20Guidance) NeoGenomics revised FY 2025 guidance, lowering revenue and increasing net loss projections, while maintaining a stable Adjusted EBITDA outlook [Full Year 2025 Guidance Update](index=3&type=section&id=Full%20Year%202025%20Guidance%20Update) NeoGenomics revised FY 2025 guidance, lowering consolidated revenue and increasing projected net loss, with a slight adjustment to Adjusted EBITDA Full Year 2025 Financial Guidance (in millions) | Metric | FY 2024 Actual (Millions) | Previously Revised FY 2025 Guidance (Low-High, Millions) | Current FY 2025 Guidance (Low-High, Millions) | YOY % Change from FY 2024 (Low-High) | | :----------------- | :------------------------ | :------------------------------------------------------- | :-------------------------------------------- | :----------------------------------- | | Consolidated revenue | $661 | $747 - $759 | $720 - $726 | 9% - 10% | | Net loss | $(79) | $(85) - $(77) | $(116) - $(108) | 47% - 37% | | Adjusted EBITDA | $40 | $55 - $58 | $41 - $44 | 3% - 10% | - The company's net loss guidance for FY 2025 was significantly increased, now projected to be between **$(116) million and $(108) million**, compared to the previous guidance of $(85) million to $(77) million[10](index=10&type=chunk) - Consolidated revenue guidance was slightly lowered to a range of **$720 million to $726 million**, from the previous range of $747 million to $759 million[10](index=10&type=chunk) [Non-GAAP Financial Measures](index=8&type=section&id=Non-GAAP%20Financial%20Measures) NeoGenomics uses non-GAAP measures and reconciliations for transparency into core operating performance, excluding non-recurring or non-operational items [Use and Definitions](index=8&type=section&id=Use%20and%20Definitions) Non-GAAP measures offer transparency into operating performance by excluding non-core or inconsistent items, assisting internal decisions and investor evaluation - Non-GAAP measures exclude certain income/expense items not directly attributable to core operating results or inconsistent in amounts and frequency, facilitating analysis of core test-level operating results[24](index=24&type=chunk) - Adjusted EBITDA is defined as net (loss) income before interest, tax, depreciation, amortization, stock-based compensation, and other specific non-operating items[25](index=25&type=chunk) - Adjusted Gross Profit Margin, Adjusted Net (Loss) Income, and Adjusted Diluted EPS are also defined with specific adjustments to GAAP figures[26](index=26&type=chunk)[27](index=27&type=chunk)[28](index=28&type=chunk) [Reconciliation of GAAP to Non-GAAP Measures](index=9&type=section&id=Reconciliation%20of%20GAAP%20to%20Non-GAAP%20Measures) Detailed reconciliations from GAAP net loss to non-GAAP metrics are provided for Q2, YTD, and full-year guidance, highlighting adjustments like impairment and stock-based compensation [EBITDA and Adjusted EBITDA Reconciliation](index=9&type=section&id=EBITDA%20and%20Adjusted%20EBITDA%20Reconciliation) Q2 2025 GAAP net loss increased significantly, leading to negative EBITDA, but Adjusted EBITDA remained stable after key adjustments Q2 2025 vs Q2 2024 EBITDA and Adjusted EBITDA (in thousands) | Metric | Q2 2025 (thousands) | Q2 2024 (thousands) | | :----------------- | :------------------ | :------------------ | | Net loss (GAAP) | $(45,092) | $(18,642) | | EBITDA (non-GAAP) | $(29,882) | $(3,836) | | Adjusted EBITDA (non-GAAP) | $10,675 | $10,869 | - Key adjustments for Q2 2025 included **$20,041 thousand in impairment charges** and **$12,215 thousand in stock-based compensation expense**[29](index=29&type=chunk) [Gross Profit and Adjusted Gross Profit Margin Reconciliation](index=10&type=section&id=Gross%20Profit%20and%20Adjusted%20Gross%20Profit%20Margin%20Reconciliation) GAAP gross profit margin slightly decreased, but Adjusted Gross Profit Margin, excluding amortization and stock-based compensation, showed stable Q2 2025 performance Q2 2025 vs Q2 2024 Gross Profit and Margin (in thousands) | Metric | Q2 2025 (thousands) | Q2 2024 (thousands) | Change (%) | | :------------------------- | :------------------ | :------------------ | :--------- | | Gross Profit (GAAP) | $77,258 | $72,494 | 6.6% | | Adjusted Gross Profit (non-GAAP) | $82,372 | $77,761 | 5.9% | | Gross Profit Margin (GAAP) | 42.6% | 44.1% | -1.5 pp | | Adjusted Gross Profit Margin (non-GAAP) | 45.4% | 47.3% | -1.9 pp | - Adjustments to cost of revenue for Q2 2025 included **$4.8 million of amortization of acquired intangible assets** and **$0.3 million of stock-based compensation**[33](index=33&type=chunk) [Net Loss and EPS to Adjusted Net Loss and Adjusted EPS Reconciliation](index=11&type=section&id=Net%20Loss%20and%20EPS%20to%20Adjusted%20Net%20Loss%20and%20Adjusted%20EPS%20Reconciliation) Q2 2025 reconciliation highlights a significant difference between GAAP and Adjusted net loss/EPS, mainly from excluding impairment, stock-based compensation, and amortization Q2 2025 vs Q2 2024 Net Loss and EPS Reconciliation (in thousands, except per share) | Metric | Q2 2025 (thousands) | Q2 2024 (thousands) | | :------------------------- | :------------------ | :------------------ | | Net loss (GAAP) | $(45,092) | $(18,642) | | Adjusted net income (non-GAAP) | $3,589 | $4,424 | | Diluted EPS (GAAP) | $(0.35) | $(0.15) | | Adjusted diluted EPS (non-GAAP) | $0.03 | $0.03 | - Significant adjustments for Q2 2025 included **$20,041 thousand for impairment charges** and **$12,215 thousand for stock-based compensation expense**[36](index=36&type=chunk) [Financial Guidance Reconciliation](index=13&type=section&id=Financial%20Guidance%20Reconciliation) FY 2025 guidance reconciliation shows the substantial impact of non-GAAP adjustments, like amortization and stock-based compensation, in converting GAAP net loss to positive Adjusted metrics FY 2025 Financial Guidance Reconciliation (in thousands, except per share) | Metric | Low Range (thousands) | High Range (thousands) | | :------------------------- | :-------------------- | :--------------------- | | Net loss (GAAP) | $(116,000) | $(108,000) | | Adjusted net income (non-GAAP) | $10,000 | $15,000 | | Adjusted EBITDA (non-GAAP) | $41,000 | $44,000 | | Net loss per diluted share (GAAP) | $(0.91) | $(0.84) | | Adjusted diluted EPS (non-GAAP) | $0.08 | $0.12 | - Key adjustments for FY 2025 guidance include **$32,000 thousand for amortization of intangibles**, **$43,000-$46,000 thousand for stock-based compensation**, and **$48,000 thousand for other one-time expenses**[39](index=39&type=chunk) [Supplemental Information](index=14&type=section&id=Supplemental%20Information) This section provides additional details on clinical test volumes and revenue, highlighting growth in both tests performed and average revenue per test [Clinical Tests Performed and Revenue](index=14&type=section&id=Clinical%20Tests%20Performed%20and%20Revenue) NeoGenomics reported strong Q2 2025 growth in clinical tests and average revenue per test, indicating increased volume and higher-value testing Q2 2025 Clinical Tests Performed and Revenue | Metric | Q2 2025 | Q2 2024 | Change (%) | | :----------------------------------- | :-------- | :-------- | :--------- | | Clinical excluding Pathline: Number of tests performed | 343,005 | 311,670 | 10.1% | | Clinical excluding Pathline: Average revenue/test | $465 | $454 | 2.4% | | Clinical including Pathline: Number of tests performed | 356,630 | 311,670 | 14.4% | | Clinical including Pathline: Average revenue/test | $461 | $454 | 1.5% | - The average revenue per clinical test increased by **2.4% (excluding Pathline)** and **1.5% (including Pathline)** in Q2 2025, reflecting higher value tests, including NGS, and strategic reimbursement initiatives[3](index=3&type=chunk)[41](index=41&type=chunk) [Corporate Information](index=3&type=section&id=Corporate%20Information) This section provides an overview of NeoGenomics, includes forward-looking statement disclaimers, and offers contact details for investor and media relations [About NeoGenomics, Inc.](index=3&type=section&id=About%20NeoGenomics%2C%20Inc.) NeoGenomics is a premier cancer diagnostics company specializing in genetics testing and information services, offering a comprehensive oncology-focused menu - NeoGenomics is a premier cancer diagnostics company specializing in cancer genetics testing and information services[12](index=12&type=chunk) - The company offers one of the most comprehensive oncology-focused testing menus, serving oncologists, pathologists, hospital systems, academic centers, and pharmaceutical firms[12](index=12&type=chunk) - NeoGenomics operates CAP-accredited and CLIA-certified laboratories throughout the US and a CAP-accredited full-service laboratory in Cambridge, United Kingdom[12](index=12&type=chunk) [Forward-Looking Statements](index=4&type=section&id=Forward-Looking%20Statements) This section provides a standard disclaimer for forward-looking statements, cautioning investors about inherent risks that could cause actual results to differ from projections - Forward-looking statements address matters such as 2025 financial guidance, seasonality impacts, and long-range strategic objectives[15](index=15&type=chunk) - These statements are subject to risks and uncertainties, including the company's ability to implement initiatives, gain customers, offer new tests, integrate acquisitions, manage seasonality, and execute strategic priorities[15](index=15&type=chunk) - Investors are cautioned not to place undue reliance on these statements and are encouraged to review the company's SEC filings for a discussion of risks[16](index=16&type=chunk) [Investor Relations & Media](index=3&type=section&id=Investor%20Relations%20%26%20Media) This section provides contact information for investor relations and media inquiries, plus details for accessing the Q2 2025 results webcast and conference call - A webcast and conference call to discuss Q2 2025 results was scheduled for **Tuesday, July 29, 2025, at 8:30 a.m. Eastern Time**[11](index=11&type=chunk) - Investor contact information is provided for Kendra Webster at InvestorRelations@neogenomics.com[17](index=17&type=chunk) - Media contact information is provided for Andrea Sampson at asampson@sampsonprgroup.com[17](index=17&type=chunk)

Core Viewpoint - Pomerantz LLP is investigating claims of potential securities fraud or unlawful business practices involving Zeo Energy Corp and its officers or directors [1] Group 1: Company Compliance Issues - On May 29, 2025, Zeo announced it received a notice from Nasdaq regarding non-compliance with periodic filing requirements due to the failure to file its Quarterly Report on Form 10-Q by the due date of May 15, 2025 [2] - Following this announcement, Zeo's stock price decreased by $0.34 per share, representing a decline of 9.91%, closing at $3.09 per share on May 30, 2025 [2] Group 2: Legal Context - Pomerantz LLP is recognized as a leading firm in corporate, securities, and antitrust class litigation, with a history of fighting for victims of securities fraud and corporate misconduct [3]